Evofem - MPT Vaginal Gel

We are collaborating with Orion Biotechnology to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002, in Phexxi with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women. This collaboration will focus on determining compatibility and stability of OB-002 in Phexxi and is expected to yield results in the third quarter of 2022. Assuming positive results, the Company and Orion will seek government and philanthropic funding for subsequent clinical trials of the MPT vaginal gel product candidate.